Welcome to our dedicated page for Prestige Consumer Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consumer Healthcare stock.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading provider of over-the-counter (OTC) healthcare products, serving consumers across North America and globally in markets such as Australia, New Zealand, and Asia. The company boasts a diverse portfolio of trusted brands that include household names like Clear Eyes, DenTek, Summer's Eve, Monistat, BC, Goody's, and Dramamine, among others. With a focus on product innovation and quality, Prestige Consumer Healthcare aims to enhance the lives of its customers worldwide.
Founded on the principles of trust and reliability, Prestige Consumer Healthcare is recognized as the largest independent provider of OTC healthcare products in North America. The company's success is attributed to its ability to remain agile while maintaining detailed attention to its extensive range of product offerings. This is reflected in the company's consistent efforts to improve and create products that align with the ever-evolving needs of consumers and their families.
Recent achievements for Prestige Consumer Healthcare include strong financial performances, as evidenced by their second quarter fiscal 2024 results. The company reported revenues of $286.3 million and a net income of $53.6 million, highlighting a robust growth in earnings per share. This was driven by the diverse and leading portfolio of brands, along with broad distribution and a solid financial model. Strong performances in categories such as Cough & Cold and Ear & Eye Care contributed significantly to these results.
In terms of financial health, Prestige Consumer Healthcare continues to demonstrate strong cash flow generation. For the second quarter of fiscal 2024, the company reported net cash provided by operating activities at $62.5 million and a non-GAAP free cash flow of $59.5 million. Debt reduction and disciplined capital deployment remain key priorities, with the company reducing its net debt to approximately $1.2 billion and achieving a leverage ratio of 3.0x.
Partnerships and global reach are also integral to Prestige Consumer Healthcare's strategy. The company generates around 85% of its total revenue from North America, with the remaining sales coming from international markets. Key brands such as Hydralyte in Australia and niche consumer health products in other regions underscore the company's global presence and commitment to meeting diverse healthcare needs.
Looking ahead, Prestige Consumer Healthcare is optimistic about its growth prospects, reaffirming its fiscal 2024 outlook with expectations of continued sales and earnings growth. The company remains well-positioned to create long-term shareholder value through stable organic growth and strategic capital allocation.
Prestige Consumer Healthcare Inc. (NYSE:PBH) has finalized its acquisition of TheraTears and other consumer brands from Akorn Operating Company for $230 million in cash. The asset purchase is expected to enhance Prestige's eye care portfolio, bringing approximately $60 million in annual revenue and contributing $20 million in EBITDA. The transaction is valued at under 10x pro-forma EBITDA, providing anticipated tax benefits of ~$30 million. The acquisition was financed through available cash, an Asset Based Loan, and refinancing of its term loan maturing in 2028.
Prestige Consumer Healthcare (NYSE:PBH) announced a $230 million cash acquisition of a portfolio from Akorn Operating Company, including the TheraTears brand. This acquisition is projected to generate approximately $60 million in annual revenue and $20 million in EBITDA. The transaction, expected to close in fiscal Q2, offers tax benefits of about $30 million and is valued at less than 10x pro-forma EBITDA. The TheraTears brand, a leader in the dry eye segment, aligns with Prestige's growth strategy and operational model.
Prestige Consumer Healthcare (PBH) reported strong fiscal 2021 results, exceeding guidance with revenue of $943.4 million and record diluted earnings per share (EPS) of $3.25. In Q4, revenues were $237.8 million, down 5.4% year-over-year, while net income was $35.5 million. The company generated $213.4 million in adjusted free cash flow and provided a positive outlook for fiscal 2022, forecasting revenues of $957 to $962 million and adjusted EPS of $3.58 or more.
Prestige Consumer Healthcare (NYSE:PBH) will release its fiscal 2021 fourth quarter and year-end earnings on May 6, 2021, before market opens. A conference call will follow at 8:30 a.m. ET to discuss the results. Participants can join via phone or listen to a webcast on the Investor Relations page of the company’s website. Telephonic replays will be available for a week post-call. Prestige markets various consumer healthcare products across North America and internationally, with well-known brands like Monistat®, Summer’s Eve®, and Dramamine®.
Prestige Consumer Healthcare Inc. (NYSE: PBH) has priced an upsized offering of $600 million in 3.750% senior notes due 2031, to be completed by March 1, 2021. The proceeds will be used to redeem all outstanding 6.375% senior notes due 2024. The offering is being made only to qualified institutional buyers under Rule 144A of the Securities Act. Prestige Consumer Healthcare markets a diverse range of consumer healthcare products across various countries.
Prestige Consumer Healthcare Inc. (NYSE: PBH) announced a private offering of up to $500 million in new senior notes due 2031 through its subsidiary, Prestige Brands, Inc. The funds will be utilized to redeem $600 million of outstanding 6.375% Senior Notes due 2024 and cover related expenses. The redemption is contingent upon the completion of the new notes offering. These notes will be offered only to qualified institutional buyers under Rule 144A and Regulation S of the Securities Act, and it does not constitute an offer to sell or solicit an offer to buy.
Prestige Consumer Healthcare (NYSE:PBH) reported its fiscal Q3 2021 results, highlighting revenues of $238.8 million, a slight decline of 1.1% year-over-year. Despite this, net income grew to $40.9 million, up from $38.1 million, with diluted EPS of $0.81 compared to $0.75 last year. The company raised its full-year revenue outlook to approximately $935 million, driven by steady consumption across key brands and a strategic focus on brand investments. Cash flow also improved, with net cash from operating activities increasing by 10% to $176.5 million for the first nine months.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2021 third quarter earnings on February 4, 2021, before market opening. A conference call to discuss these results will follow at 8:30 a.m. ET. U.S. and Canadian participants can call 844-233-9440, while international callers can reach 574-990-1016, using conference ID 4948099. Both a live Internet webcast and an archived replay will be available on the company's Investor Relations page. Prestige markets a diverse portfolio of healthcare products in North America and internationally.
Prestige Consumer Healthcare (PBH) reported Q2 FY2021 revenue of $237.4 million, roughly unchanged from the previous year. Diluted EPS rose to $0.88, a 35% increase compared to $0.65 in Q2 FY2020. The company achieved net income of $44.6 million, a notable uptick from $33.3 million year-over-year. Debt reduction continued with a $74 million paydown this quarter. The FY2021 revenue outlook is approximately $925 million, driven by core brand growth, despite COVID-19-related consumption disruptions.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2021 second quarter earnings on November 5, 2020, before market open. A conference call is scheduled for the same day at 8:30 a.m. ET, where management will discuss the results. Participants in the U.S. can dial 844-233-9440 or 574-990-1016 internationally, using conference ID 4199894. This announcement is expected to provide insights into the company's financial performance, including potentially key metrics such as revenue and earnings per share.
FAQ
What is the current stock price of Prestige Consumer Healthcare (PBH)?
What is the market cap of Prestige Consumer Healthcare (PBH)?
What does Prestige Consumer Healthcare Inc. do?
Where does Prestige Consumer Healthcare generate most of its revenue?
What recent financial results has Prestige Consumer Healthcare reported?
How is Prestige Consumer Healthcare managing its debt?
What are some of the key brands under Prestige Consumer Healthcare?
What is the company's approach to product innovation?
What is the company's outlook for the future?
How does Prestige Consumer Healthcare support its global operations?
What is the company's financial strategy?
How can investors access the company's financial updates?
